Skip to main content
PLOS One logoLink to PLOS One
. 2021 Aug 13;16(8):e0256043. doi: 10.1371/journal.pone.0256043

Are neighbourhoods of tuberculosis cases a high-risk population for active intervention? A protocol for tuberculosis active case finding

Bachti Alisjahbana 1,2, Raspati Cundarani Koesoemadinata 1,3,*, Panji Fortuna Hadisoemarto 1,4, Bony Wiem Lestari 1,3,4, Sri Hartati 1, Lidya Chaidir 1,5, Chuan-Chin Huang 6, Megan Murray 6, Philip Campbell Hill 7, Susan Margaret McAllister 7
Editor: Seyed Ehtesham Hasnain8
PMCID: PMC8362935  PMID: 34388190

Abstract

Background

Indonesia has the second largest tuberculosis (TB) burden globally. Attempts to scale-up TB control efforts have focused on TB households. However, in most high burden settings, considerable Mycobacterium tuberculosis (Mtb) transmission occurs outside TB households. A better understanding of transmission dynamics in an urban setting in Indonesia will be crucial for the TB Control Program in scaling up efforts towards elimination of TB in a more targeted way. Therefore, the study aims to measure TB prevalence and incidence in household contacts and neighbourhoods in the vicinity of known TB cases and to assess their genomic and epidemiological relatedness.

Methods and analysis

Individuals (~1000) living in the same household as a case diagnosed with pulmonary TB (n = 250) or in a neighbouring household (~4500 individuals) will be screened for TB symptoms and by chest x-ray. Two sputum samples will be collected for microbiological analysis from anyone with a productive cough. Any person found to have TB will be treated by the National TB Control Program. All those with no evidence of TB disease will have a repeat screen at 12 months. Whole-genome sequencing (WGS) and social network analysis (SNA) will be conducted on Index cases and contacts diagnosed with TB.

Introduction

Tuberculosis (TB) remains a leading cause of infection globally, with an estimated 10 million new cases of disease and 1.2 million deaths from TB in 2019 [1]. To eliminate TB, we need to identify target populations most at risk so that enhanced intervention can drive the incidence of TB down across the wider population. Many attempts to intensify TB control efforts have focused on TB households [24]. However, we now know that in most high burden settings, the majority of Mycobacterium tuberculosis (Mtb) transmission occurs in the community where there are vastly greater numbers of human encounters [5] that often share socio-economic risk factors that are correlated with TB [6, 7]. In a feasibility study in Bandung, Indonesia [8] we followed individual TB patients back to their communities. We found an incidence rate of self-reported TB of 649 per 100,000/year in TB household contacts, 675 in neighbouring households, and 325 in randomly selected neighbourhoods [8].

TB disease occurs through two distinct mechanisms (primary progression and reactivation) that require different interventions. Soon after exposure to Mtb, a small proportion of people develop TB disease (primary progression) and approximately 50% of them are latently infected but remain well. Of these latently infected people, 5% develop TB disease during their lifetime (reactivation) [911]. Early diagnosis and six months of multi-drug treatment of TB disease reduces transmission to case contacts, and preventive treatment of latent TB for as little as three months reduces reactivation in infected contacts by up to 90% [12, 13]. Both strategies are essential for TB elimination [14]. If neighbourhoods around TB cases have high rates of TB, then this is likely to be due to a particular mix of primary progression and reactivation disease.

Indonesia has the second largest TB burden globally (prevalence estimate 647/100,000 population) [15]. Bandung City, in the province of West Java, has a population of approximately 2.4 million inhabitants. Much of the diagnosis and treatment of TB is carried out in Community Health Centres (CHCs) and public hospitals. Diagnosis by sputum microscopy and provision of anti-TB medication in these health facilities is provided free of charge by the National TB Program (NTP). Approximately 2200 sputum smear-positive TB patients are notified per year from the 80 CHCs located throughout the city (~28 TB patients per CHC), each of which have a defined catchment area.

We present a protocol of a study aimed to measure the TB prevalence and incidence in households and neighbourhoods of a known TB case. We also aim to assess how genomic and epidemiological relatedness varies between TB cases from household contacts, and those from the neighbourhoods.

Methods

Study design

The study will interlink with an ongoing randomised trial of an intervention to increase notifications of TB cases from private practitioners (PP) [16]. Thirty-six CHC areas in Bandung have been randomised 1:1 to receive a multi-component intervention with PPs or continue the standard practice. Our study will recruit participants from six of the intervention areas included in the trial selected to be in proximity to each other. The study consists of two main components: 1) a prospective cohort study; and 2) whole-genome sequencing (WGS) and social network analyses (SNA) (Fig 1).

Fig 1. Overall study schematic.

Fig 1

1) Prospective cohort study

Study participation and recruitment. From 250 bacteriologically-proven TB patients (Index case) living within one of the six selected CHC areas of Bandung City (as described above), we will conduct active case finding among household contacts (approximately four people per household) and neighbourhood members. Trained research staff will interview all persons aged 10 years and above living in the same household as the Index case, as well as all those living in the five houses closest to the Index case. We will record all subjects in the target households and assess their eligibility. We will not exclude any person with extra-pulmonary TB or being re-treated for TB for screening or follow-up. We will exclude any person in a household who normally lives at another location, or children under the age of 10 years.

The TB nurse in each recruitment site (CHC or hospital) will identify potential Index cases, ensure they are resident in the selected area and seek consent for their contact details to be forwarded for the study. Research staff will then contact consenting Index cases to arrange a time to visit them and their household when most household members are likely to be present. At the visit, further information will be provided and written informed consent obtained. The Index case will also be informed that we wish to contact neighbourhood households and their consent sought before proceeding. Research staff will identify five houses that are the closest in proximity from the Index case house. Within each identified neighbourhood household, the same procedure of informed consent will be followed. The research staff will be instructed not to reveal the identity of the Index case. Consent for any household members aged between 10 and 18 years will be sought from their parent or guardian.

Data collection and screening algorithm. For each Index case, socio-demographic information and results from their Acid-fast bacilli (AFB) smear and/or Xpert MTB/RIF testing at the CHC or hospital will be obtained. Sputum samples will be sent to the research laboratory for culture and storage. From each consenting household contact a symptom screen will be undertaken (Fig 2) as well as enquiry about any history of TB, whether they are on any TB preventive therapy, have any other immunocompromised medical condition, and their socio-demographic information (age, gender, ethnicity, smoking status). The location of each household will be recorded using an electronic geographic coordinate system. Any person with symptoms suggestive of TB (weight loss, night sweats, fever, chest discomfort or pain) will undergo clinical assessment. Any person with a productive cough of any duration will be asked to provide two sputum samples for AFB smear and/or Xpert MTB/RIF testing, and Mtb culture [17, 18]. All participants will be offered a chest x-ray, followed by sputum examination if the x-ray has changes suggestive of TB. Chest x-ray reports will be read by a radiologist. Cases with a radiology report showing indication of TB without bacteriology positivity will be consulted to an infectious disease specialist to determine whether they should receive TB treatment or not. All diagnostic procedures and treatment for any person found to have TB will be undertaken according to National TB guidelines.

Fig 2. Baseline screening algorithm.

Fig 2

Follow-up. All participants with no evidence of TB at baseline will be contacted by phone approximately four-monthly to ask whether they have been diagnosed with TB in the interim. Also, to enable the study team to capture the sputum sample and obtain a culture at the time of diagnosis, household contacts will be given a referral card with the study contact details they can show to any CHC or hospital should they present with any TB symptoms or undergo any TB related diagnostic tests. At 12 months a repeat in-person symptom screen will be done (Fig 3). If an individual within a household leaves the neighbourhood area and cannot be followed-up, the approximate date they left will be ascertained from other household members. If a whole household leaves the area before the 12-month follow-up and are unable to be contacted, an approximate date will be confirmed from neighbours.

Fig 3. Follow-up screening algorithm.

Fig 3

2) Whole-genome sequencing and social network analysis

From each household contact who is diagnosed with TB, as well as Index cases, an interview will be undertaken using a social network questionnaire, and sputum cultured for Mtb will undergo WGS to ‘fine map’ their relatedness [19]. We will use the BWA-MEM algorithm to map the sequence data to the H37Rv reference genome. Variants will be called using Pilon (v1.22). We will assign a call as missing if the valid depth at a specific site is less than 12, if the mean read mapping quality at the site does not reach seven, or if none of the alternative alleles account for at least 85% of the valid coverage.

Pairwise genetic distances between each TB patient will be determined, after removing single-nucleotide polymorphisms (SNPs) in highly repetitive genes such as the PE/PPE genes and loci under strong selection. [20, 21]. For all pairs, we will obtain the shortest travel time between two points as an approximation of the geographic distance using Open Source Routing Machine, a publicly available tool that analyses Open Street Map road network data. We will assess the relationship between geographic and genetic distance across all pairwise samples to determine the relative contribution of close versus distant contacts in TB transmission. For five definitions of SNPs distances (0–1, 2–3, 4–5, 6–10, and 11–30 SNPs different), we will first compare the odds of genetic relatedness at each of the five levels among pairs within the household, pairs within the neighbourhood, and pairs from different neighbourhoods. We will repeat the same but classifying the pairs in to five categories (within the household, 0–5, 5–10, 10–20, and 20 or more minutes of travel time apart). We will also determine whether any of the household contacts share common meeting places such as employment venues, places of worship, markets, or restaurants.

Sample size

Prevalence in neighbourhoods

The community estimate of TB prevalence from the Indonesian National Prevalence Survey result for Java was 0.5% (95% CI 0.4 to 0.6%) [22]. We expect a higher rate among TB neighbourhoods, and pragmatically (to justify a policy change), a prevalence of approximately 1.25% culture positive TB cases will be needed in the neighbourhoods. With 4500 neighbourhood participants, the 95% confidence interval around 1.25% will be 0.9 to 1.6%, comfortably above the community estimate.

Genomic relatedness

We expect a maximum of 10% (95% CI 6.3–13.7%) of 250 community diagnosed Index TB cases will have an Mtb isolate that is genomically ‘identical’ to another Index case, compared to approximately 60% of Index TB case/household contact TB case pairs. Percentages for Index case/neighbourhood case pairs will lie between these values. Assuming we identify 35 culture-positive cases in contacts in 250 households and 75 culture-positive cases in neighbourhoods, we will have >95% power to detect significant differences (p = 0.05 level of significance), in percent genomically ‘identical’, for comparisons between community and Index TB case/household TB case pairs and between community and Index TB case/neighbourhood case pairs. We will also have over 80% power to detect a significant difference for a household versus neighbourhood comparison, if 60% or more of Index case/household case pairs are genomically ‘identical’ and 30% or less of Index case/neighbourhood case pairs are genomically ‘identical’.

Outcome measures and statistical analysis

We will categorize TB for Index and household/neighbourhood contacts into four categories: definite TB, probable TB, possible TB, and not TB. Subjects are categorised as definite TB if their Mtb culture or Xpert MTB/RIF positive; probable TB if they have TB symptoms, chest x-ray suggestive of TB, and AFB smear-positive but culture negative/not done; possible TB if they have TB symptoms and/or chest x-ray suggestive of TB but all bacteriology examinations negative/not done; and not TB if there was no evidence of TB on a symptom review or investigations. Chest x-rays will be classified as normal, suggestive active TB, suggestive inactive TB, or abnormal not TB based on the radiology report.

The key outcomes of this study are to estimate the TB prevalence and incidence in neighbourhoods around known TB cases, compared to households of known TB cases. TB prevalence defined as the number, percent and 95% confidence intervals (CI) of positive TB cases, according to each TB definition (definite, probable, possible), will be estimated. These proportions will be compared between households, neighbourhoods, and estimates from the Indonesian National Prevalence Survey for Java/Bali. TB incidence defined as incidence rates and 95% CI of positive TB cases according to each TB definition (definite, probable, possible), will be calculated per 1000 person-days. Person-days will be calculated as the days from the date of baseline examination to either: a) the date of TB diagnosis, b) date of death (if died) as reported by household member, c) date of 12-month follow-up examination, or d) date left the neighbourhood area for any household member who has left the area before the 12-month follow-up.

Data handling

Information collected during interviews will be recorded on an electronic case report form (CRF) or paper-based CRF in case of internet connection problem. Standard operating procedures on interview procedure and data entry will provide the necessary guidelines for research staff. A monthly check will be done for data completeness and accuracy. All databases and data collection tablets will be password protected.

Ethical considerations

Research ethics approval

The protocol and consent forms have been reviewed and approved by the University of Otago Human Ethics Committee (reference number H20-054) on 28 May 2020, translated into Bahasa Indonesia and approved by the Universitas Padjadjaran Health Research Committee (reference number 1129/UN6.KEP/EC/2020) on 3 December 2020.

Confidentiality

Participants will be assured of their confidentiality, that no identifiable information will be shared with anyone outside of the research team, and that they can refuse to answer any question if they feel uncomfortable. Each study participant will be given a unique study identification number that will be on all study documentation and in the database. The names and contact details of participants will be required in order to contact them for the 12-month follow-up interview, but these details will only be known to the relevant research nurse. The database with identifiable names and addresses will be separate from the main database that is available to researchers for the analysis. Signed consent forms will be stored in a locked cabinet.

Potential risks and benefits

TB continues to be a stigmatising disease and therefore Index cases may feel exposed and not wish to be identified. This risk will be minimised by the Index case first being asked by CHC staff if they are willing for their name and contact details to be given to the research staff. At the visit, Index cases will be asked for their consent to screen their household members, as well as neighbouring household members. They will be given reassurance that their identity and their TB status will not be revealed to neighbouring households and staff will be trained in issues of confidentiality and follow standard operating procedures. All participants will be informed about the study and given the opportunity to discuss it with their families before giving their consent. COVID-19 continues to be prevalent in Indonesia, therefore strict safety protocols will be adhered to by the research team to prevent the risk of transmission.

Discussion

The World Health Organization (WHO) 2020 Global TB Report showed Indonesia had the second highest TB incidence in absolute numbers [1]. In 2015, the National TB Program budget was estimated to be 133 million US dollars, much of which is unfunded [15]. This study will confirm whether neighbourhoods in the vicinity of routinely diagnosed TB index cases constitute a high-risk sub-population that may warrant active intervention to enhance TB control. Evidence provided will be crucial for the Indonesian TB Control Program in scaling up efforts towards the elimination of TB in a targeted and cost-effective way.

The combination of high precision genotyping, expanded social network questionnaires, and network analyses provides the opportunity to explore Mtb transmission. Genomic and social network analyses will provide important information to guide the design of possible interventions that may include active case finding, preventive treatment, and/or enhanced infection control measures in specific locations. For example, if ‘recent’ transmission of Mtb from index case households to neighbourhoods is indicated as explaining a large component of high neighbourhood prevalence, an intensive intervention of active case finding for early diagnosis and treatment would be warranted. If transmission ‘hotspots’ within the neighbourhoods can be identified, infection control measures could be considered. If high prevalence and incidence of TB is confirmed but there is a relatively low rate of genomic match within neighbourhoods, it may be that socioeconomic factors that promote reactivation are predominant. An intervention of screening for latent TB infection and initiation of preventive treatment to reduce the possibility of reactivation could be considered, or the focus could be on socioeconomic factors themselves, as suggested by WHO as part of the global strategy to End TB [23].

The proportion of TB cases that can be included in the analysis will be crucial to the ability to interpret these data. As COVID-19 continues to be prevalent in Indonesia, it is possible that recruitment and follow-up will be hindered with fewer than expected numbers being included in the study. This information will be closely monitored and every attempt made to follow-up participants through regular phone contact.

Conclusions

The study results will provide crucial information to guide the design of possible active case finding interventions to enhance TB control in Indonesia.

Acknowledgments

We would like to acknowledge Yudi Mulyana Hidayat, the Dean of Faculty of Medicine, Universitas Padjadjaran, and Ahyani Raksanegara, the Head of Bandung City Health Office for their support to carry out this project.

Funding Statement

Funding for this research comes from: 1. The e-Asia Joint Research Program administered through the Health Research Council of New Zealand, Contract No. 19/897 (award receiver: SMM). URL: https://www.the-easia.org/ 2. Indonesian Research and Technology Grant/National Research and Innovation Agency administered through Universitas Padjadjaran, Contract No 1827/UN6.3.1/LT/2020 (award receiver: BA). URL: https://www.brin.go.id/ The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.WHO. Global tuberculosis report 2020. 2020;634.
  • 2.Fox GJ, Nhung N V., Sy DN, Hoa NLP, Anh LTN, Anh NT, et al. Household-Contact Investigation for Detection of Tuberculosis in Vietnam. N Engl J Med. 2018;378(3):221–9. doi: 10.1056/NEJMoa1700209 [DOI] [PubMed] [Google Scholar]
  • 3.Eang MT, Satha P, Yadav RP, Morishita F, Nishikiori N, Van-Maaren P, et al. Early detection of tuberculosis through community-based active case finding in Cambodia. BMC Public Health [Internet]. 2012;12(1):1. Available from: BMC Public Health doi: 10.1186/1471-2458-12-469 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Shapiro AE, Variava E, Rakgokong MH, Moodley N, Luke B, Salimi S, et al. Community-based targeted case finding for tuberculosis and HIV in household contacts of patients with tuberculosis in South Africa. Am J Respir Crit Care Med. 2012;185(10):1110–6. doi: 10.1164/rccm.201111-1941OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Martinez L, Shen Y, Mupere E, Kizza A, Hill PC, Whalen CC. Transmission of Mycobacterium Tuberculosis in Households and the Community: A Systematic Review and Meta-Analysis. Am J Epidemiol. 2017;185(12):1327–39. doi: 10.1093/aje/kwx025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hill PC, Whalen CC. Non-clinical factors associated with TB: Important for DOTS impact evaluation and disease elimination. Trans R Soc Trop Med Hyg. 2014;108(9):523–5. doi: 10.1093/trstmh/tru114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Dye C, Lönnroth K, Jaramillo E, Williams BG, Raviglione M. Trends in tuberculosis incidence and their determinants in 134 countries. Bull World Health Organ. 2009;87(9):683–91. doi: 10.2471/blt.08.058453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.McAllister S, Wiem Lestari B, Sujatmiko B, Siregar A, Sihaloho ED, Fathania D, et al. Feasibility of two active case finding approaches for detection of tuberculosis in Bandung City, Indonesia. Public Heal Action. 2017;7(3):206–11. doi: 10.5588/pha.17.0026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018. [PubMed]
  • 10.Hill PC, Jackson-Sillah DJ, Fox A, Brookes RH, de Jong BC, Lugos MD, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One. 2008;3(1). doi: 10.1371/journal.pone.0001379 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Cohen T, Colijn C, Finklea B, Murray M. Exogenous re-infection and the dynamics of tuberculosis epidemics: local effects in a network model of transmission. J R Soc Interface. 2006; [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Vynnycky E, Borgdorff MW, Leung CC, Tam CM, Fine PEM. Limited impact of tuberculosis control in Hong Kong: Attributable to high risks of reactivation disease. Epidemiol Infect. 2008;136(7):943–52. doi: 10.1017/S0950268807008552 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Sterling TR, Villarino E, Borisov AS, Shang N, Gordin F, Bliven-sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;2155–66. doi: 10.1056/NEJMoa1104875 [DOI] [PubMed] [Google Scholar]
  • 14.Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis Infection. N Engl J Med. 2015;372(22):2127–35. doi: 10.1056/NEJMra1405427 [DOI] [PubMed] [Google Scholar]
  • 15.World Health Organization. Global tuberculosis report 2015. 2015.
  • 16.Hadisoemarto P, Lestari BW, Sharples K, Afifah N, Chaidir L, Huang C-C, et al. A public health intervention package for increasing tuberculosis notifications from private practitioners in Bandung, Indonesia (INSTEP2): A cluster-randomised controlled trial protocol. F1000Research. 2021;10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Davis JL, Cattamanchi A, Cuevas LE, Hopewell PC, Steingart KR. Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(2):147–54. doi: 10.1016/S1473-3099(12)70232-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Mase S, Ramsay A, Ng V, Henry M, Hopewell P, Cunningham J, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2007;11(5):485–95. [PubMed] [Google Scholar]
  • 19.Köser CU, Ellington MJ, Cartwright EJP, Gillespie SH, Brown NM, Farrington M, et al. Routine Use of Microbial Whole Genome Sequencing in Diagnostic and Public Health Microbiology. PLoS Pathog. 2012;8(8). doi: 10.1371/journal.ppat.1002824 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Luo T, Yang C, Peng Y, Lu L, Sun G, Wu J, et al. Whole-genome sequencing to detect recent transmission of Mycobacterium tuberculosis in settings with a high burden of tuberculosis. Tuberculosis [Internet]. 2014;94(4):434–40. Available from: 10.1016/j.tube.2014.04.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Nikolayevskyy V, Kranzer K, Niemann S, Drobniewski F. Whole genome sequencing of Mycobacterium tuberculosis for detection of recent transmission and tracing outbreaks: A systematic review. Tuberculosis [Internet]. 2016;98:77–85. Available from: 10.1016/j.tube.2016.02.009 [DOI] [PubMed] [Google Scholar]
  • 22.Ministry of Health Republic of Indonesia. National tuberculosis prevalence survey. 2014.
  • 23.Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new end TB strategy. Lancet. 2015;385(9979):1799–801. doi: 10.1016/S0140-6736(15)60570-0 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Seyed Ehtesham Hasnain

25 Jun 2021

PONE-D-21-15501

Are neighborhoods of tuberculosis cases a high-risk population for active intervention? A protocol for tuberculosis active case finding in Bandung, Indonesia

PLOS ONE

Dear Dr. Koesoemadinata,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Aug 09 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Seyed Ehtesham Hasnain

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found athttps://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please upload a copy of Figure 2 and 3, to which you refer in your text on pages 6 and 7. If the figure is no longer to be included as part of the submission please remove all reference to it within the text.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

Minor revision

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have worked on the protocol in finding the active tuberculosis cases in their neighborhoods of Bandung from Indonesia. The study measures the TB prevalence and incidence in households and neighborhoods in the vicinity of known TB cases, and to assess how genomic and epidemiological relatedness varies between TB cases from household contacts, and those from the neighborhoods. The manuscript is well designed; statistics and other analyses are performed to a high technical standard and are described in sufficient detail. Conclusions needs to be supported by the data.

Comments

1. As you have not excluded the comorbidity, did you studied what is the prevalence and incidence rate in households or neighborhoods, who have comorbidity.

2. According to prevalence neighborhoods have higher incidence rate than households, whereas genomical identity is lower in neighborhoods than households. Can you explain these and how did you find these differences?

3. What is the percentage of drop outs during the follow up in your study ?

4. No data has been generated or analyzed in the current study. You have mentioned SNA analysis, it will be more informative if you can add those images.

5. Discussion and conclusion of the study is not informative, it is poorly structured due to lack of previous studies or citations in the neighborhood. It is better to rewrite to understand easily.

6. Correct the grammatical mistakes in the manuscript.

.

Reviewer #2: Comments:

Presented study protocol may help in the findings to measure TB prevalence and incidence in household contacts as well as neighborhoods in the surrounding area of known TB cases from our society. It has been written very nicely, however few advices may improve this protocol:

• While collecting the data of socio-demographic information, author may take collect the common TB comorbidities include diabetes mellitus, smoking, alcohol-use disorders, chronic lung diseases, cancer and depression data also.

• In patient history, alcoholism and smoker status of patient as well as neighborhoods contact should be noted if possible. Because these behavior are strongly associated with TB disease and attributed to high risk of SARs in elderly and TB comorbidities patients.

• It is also advised to perform phenotypic DST to all culture positive specimens in addition of genotypic DST.

• EPTB is already excluded from this study. However, it is also advised to make a separate group for them to analyzed data considering all methodology as discussed.

Conclusion: Authors are advised to reframe.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Aug 13;16(8):e0256043. doi: 10.1371/journal.pone.0256043.r002

Author response to Decision Letter 0


22 Jul 2021

22 July 2021

Seyed Ehtesham Hasnain

Academic Editor

PLOS ONE

Dear Dr Hasnain,

Re: Manuscript PONE-D-21-15501: “Are neighbourhoods of tuberculosis cases a high-risk population for active intervention? A protocol for tuberculosis active case finding in Bandung, Indonesia”

Thank you for review of the above-stated manuscript and the opportunity to submit a revised version.

The two reviewers made helpful suggestions for improvement which we believe we have addressed in the revised paper or in our rebuttal below. We have responded to each point raised by the reviewers and have updated the manuscript, indicated as track changes.

Thank you for your consideration

Kind regards

Raspati C. Koesoemadinata

(Corresponding author)

Response to Reviewers

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Thank you. We have revised the manuscript, and we believe it complies with PLOS ONE's style requirements.

2. Please upload a copy of Figure 2 and 3, to which you refer in your text on pages 6 and 7. If the figure is no longer to be included as part of the submission please remove all reference to it within the text.

Figures 2 and 3 were uploaded with the original submission. We will upload them again with this revised submission to make sure they are accessible to the reviewers.

3. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

We uploaded the research grant review and ethical approval letters and mistakenly labelled them as "Supporting information". They are now labelled as “Other”.

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

The reference list has been checked. No changes have been made to the reference list.

Reviewer’s Comments to the Author

Reviewer #1: The authors have worked on the protocol in finding the active tuberculosis cases in their neighbourhoods of Bandung from Indonesia. The study measures the TB prevalence and incidence in households and neighbourhoods in the vicinity of known TB cases, and to assess how genomic and epidemiological relatedness varies between TB cases from household contacts, and those from the neighbourhoods. The manuscript is well designed; statistics and other analyses are performed to a high technical standard and are described in sufficient detail. Conclusions needs to be supported by the data.

Comments

1. As you have not excluded the comorbidity, did you studied what is the prevalence and incidence rate in households or neighbourhoods, who have comorbidity.

We will ask the participants about any other immunocompromised medical conditions. This information has now been added to the manuscript (lines 129-130).

2. According to prevalence neighbourhoods have higher incidence rate than households, whereas genomical identity is lower in neighbourhoods than households. Can you explain these and how did you find these differences?

In the earlier study in Bandung, we have found a higher TB incidence rate in the neighbourhoods. This study has shown us that the incidence rate of self-reported TB was 649 per 100,000/year in TB household contacts, 675 in neighbouring households, and 325 in a randomly selected community (Reference #8). Evidence from other studies also have reported the higher TB incidence in the community outside TB households (Reference #5) (Lines 54-55). We are unsure of the genomic identity of cases in households and neighbourhoods, hence the need for this study.

3. What is the percentage of drop outs during the follow up in your study?

Several measures have been put in place to minimise drop-out, such as regular phone calls to participants throughout the 12 months, having phone numbers of other household members (Lines 146-156). The estimated percentage of drop-out that may occur during the follow-up period is not known particularly during this time of the COVID-19 pandemic. This limitation has been added to the discussion (lines 300-303).

4. No data has been generated or analyzed in the current study. You have mentioned SNA analysis, it will be more informative if you can add those images.

Our manuscript is a protocol paper. Recruitment of participants has only recently started. Full results, including SNA analysis figures will be included in the future manuscripts.

5. Discussion and conclusion of the study is not informative; it is poorly structured due to lack of previous studies or citations in the neighbourhood. It is better to rewrite to understand easily.

As our manuscript is a protocol paper, it is impossible to format it according to the standard formatting of a discussion with results. We believe we have included information required by the journal in discussing the possible implications of our study and how the results might be used. Extra information has been added on limitations.

6. Correct the grammatical mistakes in the manuscript.

Thank you. We have reviewed the manuscript thoroughly and corrected the mistakes.

Reviewer #2: Comments:

Presented study protocol may help in the findings to measure TB prevalence and incidence in household contacts as well as neighbourhoods in the surrounding area of known TB cases from our society. It has been written very nicely; however few advices may improve this protocol:

1. While collecting the data of socio-demographic information, author may take collect the common TB comorbidities include diabetes mellitus, smoking, alcohol-use disorders, chronic lung diseases, cancer and depression data also.

Thank you. Yes, questions about comorbidities, other TB risk related conditions including smoking status, are included in the questionnaire. This information has now been added to the manuscript for clarity (lines 129-130). We have found a very low prevalence of alcohol use (<2%) in our previous study therefore questions about alcohol use were not included in the current study.

2. In patient history, alcoholism and smoker status of patient as well as neighbourhoods contact should be noted if possible. Because these behavior are strongly associated with TB disease and attributed to high risk of SARs in elderly and TB comorbidities patients.

Thank you. Please see the above response

3. It is also advised to perform phenotypic DST to all culture positive specimens in addition of genotypic DST.

We don’t consider that phenotypic DST is necessary for this study and its objectives. Moreover, it would increase the costs of the study beyond the budget allocated. Therefore, we will not include it in our study.

4. EPTB is already excluded from this study. However, it is also advised to make a separate group for them to analyzed data considering all methodology as discussed.

Thank you for your suggestion. Yes, we will not include EPTB patients as the index case. However, we will record all EPTB cases found during the household or the neighbourhood screening and report them in the results (Lines 105-106).

Conclusion: Authors are advised to reframe.

It is unclear what the reviewer is asking. As this is a protocol paper, a conclusion is not a requirement according to the manuscript guidelines.

Attachment

Submitted filename: Response to reviewers.docx

Decision Letter 1

Seyed Ehtesham Hasnain

29 Jul 2021

Are neighbourhoods of tuberculosis cases a high-risk population for active intervention? A protocol for tuberculosis active case finding

PONE-D-21-15501R1

Dear Dr. Koesoemadinata,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Seyed Ehtesham Hasnain

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

I have gone through the revised manuscript and also the Authors response to the comments of the reviewers. The manuscript was sent for revision and Authors have modified the manuscript keeping in mind the comments of the Reviewers. The important issue of co-morbidity has been addressed along with dropouts and incidence rates. Their response about phenotypic DST is acceptable.All grammatical and typographic errors have been taken care off by the Authors. In my view, the authors have otherwise satisfactorily addressed all the comments made by the reviewers and added all required information, and have revised the manuscript accordingly. I recommend this manuscript for publication.

Reviewers' comments:

Acceptance letter

Seyed Ehtesham Hasnain

5 Aug 2021

PONE-D-21-15501R1

Are neighbourhoods of tuberculosis cases a high-risk population for active intervention? A protocol for tuberculosis active case finding

Dear Dr. Koesoemadinata:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Seyed Ehtesham Hasnain

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to reviewers.docx


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES